Page last updated: 2024-12-11
ckd732
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Description
CKD732: angiogenesis inhibitor [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 74332265 |
| MeSH ID | M0469601 |
Synonyms (3)
| Synonym |
|---|
| ckd732 |
| [(3r,4s,5s,6r)-5-methoxy-4-[(2r,3r)-2-methyl-3-(3-methylbut-2-enyl)oxiran-2-yl]-1-oxaspiro[2.5]octan-6-yl] (e)-3-[4-[2-(dimethylamino)ethoxy]phenyl]prop-2-enoate |
| FT-0699345 |
Research Excerpts
Toxicity
| Excerpt | Reference | Relevance |
|---|---|---|
| " Sleep disturbance and gastrointestinal adverse events were more common with beloranib than with placebo; these were generally mild to moderate, transient and dose-related, and led to more early study withdrawals in participants in the group with the highest dose of beloranib." | ( Efficacy and safety of beloranib for weight loss in obese adults: a randomized controlled trial. de Looze, F; Hughes, TE; Kim, DD; Krishnarajah, J; Lillioja, S; Marjason, J; Proietto, J; Shakib, S; Stuckey, BGA; Vath, JE, 2015) | 0.42 |
| "4 mg dose was associated with increased sleep latency and mild to moderate gastrointestinal adverse events over the first month of treatment." | ( Efficacy and safety of beloranib for weight loss in obese adults: a randomized controlled trial. de Looze, F; Hughes, TE; Kim, DD; Krishnarajah, J; Lillioja, S; Marjason, J; Proietto, J; Shakib, S; Stuckey, BGA; Vath, JE, 2015) | 0.42 |
| " Beloranib, a MetAP2 inhibitor previously investigated for treatment of Prader-Willi syndrome, was associated with venous thrombotic adverse events likely resulting from drug effects on vascular endothelial cells (ECs)." | ( Preclinical Efficacy and Safety of the Novel Antidiabetic, Antiobesity MetAP2 Inhibitor ZGN-1061. Burkey, BF; Hoglen, NC; Hughes, TE; Inskeep, P; Vath, JE; Wyman, M, 2018) | 0.48 |
Compound-Compound Interactions
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| " CKD-732 was intravenously administered with the dosages of 10, 30, 40 or 50 mg/kg and the highest dosage of 50 mg/kg prolonged the hexobarbital-induced sleep time." | ( General pharmacology of CKD-732, a new anticancer agent: effects on central nervous, cardiovascular, and respiratory system. Kim, EJ; Shin, WH, 2005) | 0.33 |
| " Dosing was stopped early due to an imbalance in venous thrombotic events in beloranib-treated participants (2 fatal events of pulmonary embolism and 2 events of deep vein thrombosis) compared with placebo." | ( Effects of MetAP2 inhibition on hyperphagia and body weight in Prader-Willi syndrome: A randomized, double-blind, placebo-controlled trial. Abuzzahab, MJ; Angulo, M; Barlow, SE; Bird, LM; Butler, MG; Chan, CL; Dykens, EM; Fu, C; Hughes, TE; Kim, DD; Malloy, J; McCandless, SE; Miller, J; Myers, SE; Roof, E; Salehi, P; Scheimann, AO; Stafford, D; Styne, D; Taylor, K; Viskochil, D; Whitman, BY; Yanovski, JA; Zhuang, D, 2017) | 0.46 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (19)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (31.58) | 29.6817 |
| 2010's | 12 (63.16) | 24.3611 |
| 2020's | 1 (5.26) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 6 (31.58%) | 5.53% |
| Reviews | 4 (21.05%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 9 (47.37%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Clinical Trials (8)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase 1b Trial of Beloranib, a Novel Methionine Aminopeptidase 2 (MetAP-2) Inhibitor for Treatment of Extreme Obesity: Randomized, Double-Blind, Placebo-Controlled, Escalating Doses in Female Volunteers [NCT01372761] | Phase 1 | 25 participants (Actual) | Interventional | 2011-06-30 | Completed | ||
| Randomized, Double-Blind, Placebo Controlled, Phase 3 Trial of ZGN-440 (Subcutaneous Beloranib in Suspension) in Obese Subjects With Prader-Willi Syndrome to Evaluate Total Body Weight, Food-related Behavior, and Safety Over 6 Months [NCT02179151] | Phase 3 | 108 participants (Actual) | Interventional | 2014-09-30 | Terminated(stopped due to FDA Clinical Hold) | ||
| A Randomized, Double-Blind, Placebo-Controlled Multiple Dose Study, to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZGN-433 in Obese Volunteers [NCT01028261] | Phase 1 | 31 participants (Actual) | Interventional | 2009-12-31 | Completed | ||
| Randomized, Double-Blind, Placebo Controlled, Phase 2a Trial of ZGN-440 (Subcutaneous Beloranib in Suspension), A Novel Methionine Aminopeptidase 2 Inhibitor, in Obese Subjects With Hypothalamic Injury to Evaluate Weight Reduction and Safety Over 4 Weeks [NCT02063295] | Phase 2 | 14 participants (Actual) | Interventional | 2014-04-30 | Completed | ||
| Randomized, Double-Blind, Placebo Controlled, Parallel Dose Ranging Phase 2a Trial of ZGN-440 (Subcutaneous Beloranib in Suspension), A Novel Methionine Aminopeptidase 2 Inhibitor, in Over-weight and Obese Subjects With Prader-Willi Syndrome to Evaluate W [NCT01818921] | Phase 2 | 17 participants (Actual) | Interventional | 2013-06-30 | Completed | ||
| ZGN-440 (Beloranib for Subcutaneous Injection), A Novel Methionine Aminopeptidase 2 Inhibitor for Treatment of Obesity: A Randomized Double-Blind Placebo Controlled Dose Escalation Phase 1b Trial to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and [NCT01507077] | Phase 1 | 25 participants (Actual) | Interventional | 2011-12-31 | Completed | ||
| Randomized, Double-Blind, Placebo Controlled, Dose Ranging Phase 2 Trial of Beloranib (ZGN-440 for Injectable Suspension), A Novel Methionine Aminopeptidase 2 Inhibitor, in Obese Subjects to Evaluate Weight Reduction, Safety, and Pharmacokinetics Over 12 [NCT01666691] | Phase 2 | 160 participants (Actual) | Interventional | 2012-08-31 | Completed | ||
| Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial of ZGN-440 (Subcutaneous Beloranib in Suspension) in Obese Subjects With Type 2 Diabetes Mellitus to Evaluate Weight Reduction, Glycemic Control, Safety, and Tolerability [NCT02324491] | Phase 2 | 152 participants (Actual) | Interventional | 2014-12-31 | Terminated(stopped due to Sponsor decision to analyze available safety and efficacy data) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||